Levomefolic Acid

Summary

Levomefolic Acid (CHEMBL1231574) is an approved small molecule; indicated across 1 condition including attention deficit-hyperactivity disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 26
• Chemistry: 459.5 Da · C20H25N7O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1231574
Name	Levomefolic Acid
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	135398561
ChEBI	CHEBI:136009
Molecular formula	C20H25N7O6
Molecular weight	459.5
InChIKey	ZNOVTXRBGFNYRX-STQMWFEESA-N

SMILES: CN1[C@H](CNC2=C1C(=O)NC(=N2)N)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O

IUPAC name: (2S)-2-[[4-[[(6S)-2-amino-5-methyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid

ChEBI definition: A 5-methyltetrahydrofolic acid that has 6S-configuration.

Also known as: Acide levomefolique, Acido levomefolico, Bodyfolin, L-methylfolate, Levomefolate, Levomefolic acid, Levomefolinic acid, LMSR, Metafolin, Nutrifolin, LEVOMEFOLIC ACID, Levomefolate (calcium)

Parent form; salt/anhydrous children: CHEMBL1615371

Patent coverage: 1,292 distinct patent families (2,984 SureChEMBL compound mentions), from 5 matched compound structure(s). One matched structure accounts for 2,875 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Solute carrier organic anion transporter family member 1A3.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P70502	5.92	Ki	1200	nM	CHEMBL_ACT_11002319

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
attention deficit-hyperactivity disorder	2	MONDO:0007743	EFO:0003888

Clinical trials

Total trials: 26.

Phase distribution

Phase	Trials
Not specified	16
PHASE4	3
PHASE3	2
PHASE2/PHASE3	2
PHASE2	1
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04974151	PHASE4	RECRUITING	China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype
NCT06218030	PHASE4	RECRUITING	Adjunctive Treatment With L-methylfolate for Treatment-Resistant Generalized Anxiety Disorder: a Pilot Study
NCT04782037	PHASE4	UNKNOWN	Effectiveness of Folic Acid Supplementation in Acute Watery Diarrhea Among Children Under 5 Years of Age
NCT03059173	PHASE3	RECRUITING	Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome
NCT01331655	PHASE3	WITHDRAWN	Clinical Study of a Conventional and Flexible Extended Oral Contraceptive of EE/DRSP With or Without Metafolin in Latin America
NCT01853280	PHASE2/PHASE3	COMPLETED	L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults
NCT01976676	PHASE2/PHASE3	COMPLETED	Folic Acid vs 5-methyltetrahydrofolate (5MTHF) in Recurrent Abortion
NCT07508917	PHASE1/PHASE2	NOT_YET_RECRUITING	Effects of 5-Methyltetrahydrofolic Acid Supplementation on Maternal Health and One-Carbon Metabolism During Lactation
NCT01570088	PHASE2	COMPLETED	Bioavailability of Folic Acid Fortified Bread
NCT01031355	PHASE1	COMPLETED	Bioequivalence Study: 3 mg Estradiol Valerate (EV) With and Without Levomefolate Calcium
NCT01687127	Not specified	NOT_YET_RECRUITING	Impact of High-dose Folic Acid Supplementation on Pathways Linked to DNA Formation
NCT04723836	Not specified	ACTIVE_NOT_RECRUITING	Optimal Nutrition for Prevention of Hypertension in Pregnancy
NCT05434195	Not specified	RECRUITING	Clinical Antenatal Randomised Study to CharactErise Key Roles of TetrahydroFOLate in HyperTensive Pregnancies
NCT06641245	Not specified	NOT_YET_RECRUITING	PREconception Folic Acid Clinical Efficacy (PREFACE) Trial
NCT06935630	Not specified	RECRUITING	Comparison of The Effect of 5-MTHF and Folic Acid Supplementation in Increasing Red Blood Cell Folate in Pregnant Women
NCT00348933	Not specified	COMPLETED	Dietary Supplements for the Treatment of Angelman Syndrome
NCT00372645	Not specified	COMPLETED	Increasing Folate Status of a General Population(FOLSUPP STUDY)
NCT00626223	Not specified	COMPLETED	5-methyltetrahydrofolate Survival and Inflammation in ESRD Patients
NCT00730509	Not specified	COMPLETED	Effects of 5-Methyltetrahydrofolate and Vitamin B12 Supplemetation on Red Cell Membrane in Children With Cystic Fibrosis
NCT00853879	Not specified	TERMINATED	An Exploratory, Randomized, Blinded, Placebo-Controlled Trial of Folic Acid and L-methylfolate in Parkinson’s Disease
NCT01001559	Not specified	COMPLETED	Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis
NCT01091506	Not specified	COMPLETED	A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia Patients
NCT02133898	Not specified	COMPLETED	The Use Of L-Methylfolate As A Treatment For Depression
NCT02159261	Not specified	COMPLETED	Assess Satisfaction of Patients and Physicians With Results of Yaz Plus Treatment for 13 Cycles
NCT05699473	Not specified	TERMINATED	Bioavailability Study of Folate in Healthy Subjects
NCT05931965	Not specified	COMPLETED	Combination Therapy of Different Antidepressants With Dietary Supplements

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).